- Home
- DSP vs DCTH Comparison
DSP vs DCTH Comparison
Compare DSP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- DCTH
- Stock Information
- Founded
- DSP 1999
- DCTH 1988
- Country
- DSP United States
- DCTH United States
- Employees
- DSP N/A
- DCTH N/A
- Industry
- DSP EDP Services
- DCTH Medical/Dental Instruments
- Sector
- DSP Technology
- DCTH Health Care
- Exchange
- DSP Nasdaq
- DCTH Nasdaq
- Market Cap
- DSP 330.3M
- DCTH 387.2M
- IPO Year
- DSP 2021
- DCTH N/A
- Fundamental
- Price
- DSP $20.74
- DCTH $11.60
- Analyst Decision
- DSP Strong Buy
- DCTH Strong Buy
- Analyst Count
- DSP 7
- DCTH 4
- Target Price
- DSP $17.71
- DCTH $21.50
- AVG Volume (30 Days)
- DSP 266.9K
- DCTH 372.6K
- Earning Date
- DSP 11-12-2024
- DCTH 11-08-2024
- Dividend Yield
- DSP N/A
- DCTH N/A
- EPS Growth
- DSP N/A
- DCTH N/A
- EPS
- DSP 0.08
- DCTH N/A
- Revenue
- DSP $263,587,000.00
- DCTH $22,644,000.00
- Revenue This Year
- DSP $28.26
- DCTH $1,605.13
- Revenue Next Year
- DSP $12.19
- DCTH $111.67
- P/E Ratio
- DSP $272.33
- DCTH N/A
- Revenue Growth
- DSP 23.73
- DCTH 945.91
- 52 Week Low
- DSP $6.31
- DCTH $3.43
- 52 Week High
- DSP $21.74
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- DSP 71.06
- DCTH 57.95
- Support Level
- DSP $19.82
- DCTH $11.67
- Resistance Level
- DSP $21.25
- DCTH $13.30
- Average True Range (ATR)
- DSP 1.09
- DCTH 0.73
- MACD
- DSP -0.19
- DCTH 0.01
- Stochastic Oscillator
- DSP 71.76
- DCTH 34.60
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.